MX2022005866A - Anticuerpos biparatopicos frente a cd73. - Google Patents
Anticuerpos biparatopicos frente a cd73.Info
- Publication number
- MX2022005866A MX2022005866A MX2022005866A MX2022005866A MX2022005866A MX 2022005866 A MX2022005866 A MX 2022005866A MX 2022005866 A MX2022005866 A MX 2022005866A MX 2022005866 A MX2022005866 A MX 2022005866A MX 2022005866 A MX2022005866 A MX 2022005866A
- Authority
- MX
- Mexico
- Prior art keywords
- biparatopic
- antibodies
- antigen
- methods
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936119P | 2019-11-15 | 2019-11-15 | |
| US202063023542P | 2020-05-12 | 2020-05-12 | |
| US202063086982P | 2020-10-02 | 2020-10-02 | |
| PCT/US2020/060434 WO2021097223A2 (en) | 2019-11-15 | 2020-11-13 | Biparatopic cd73 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005866A true MX2022005866A (es) | 2022-08-15 |
Family
ID=73790235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005866A MX2022005866A (es) | 2019-11-15 | 2020-11-13 | Anticuerpos biparatopicos frente a cd73. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220403041A1 (https=) |
| EP (1) | EP4058150A2 (https=) |
| JP (2) | JP7789667B2 (https=) |
| KR (1) | KR20220100929A (https=) |
| CN (1) | CN115003385A (https=) |
| AU (1) | AU2020384305A1 (https=) |
| BR (1) | BR112022009317A2 (https=) |
| CA (1) | CA3161717A1 (https=) |
| CO (1) | CO2022008204A2 (https=) |
| IL (1) | IL292959A (https=) |
| MX (1) | MX2022005866A (https=) |
| PH (1) | PH12022551150A1 (https=) |
| WO (1) | WO2021097223A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| PE20221409A1 (es) | 2020-01-03 | 2022-09-20 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| TW202135823A (zh) | 2020-01-03 | 2021-10-01 | 美商英塞特公司 | Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法 |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| JP2025521231A (ja) * | 2022-06-08 | 2025-07-08 | シャンハイ フアオタ バイオファーマシューティカル カンパニー、リミテッド | Ｃｄ７３抗体カクテル療法 |
| CN115991772B (zh) * | 2022-08-12 | 2023-09-01 | 南京蓬勃生物科技有限公司 | 抗cd73抗体或其抗原片段及其应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6385357B2 (ja) | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| EP3204417B1 (en) * | 2014-10-10 | 2020-07-22 | Innate Pharma | Cd73 blockade |
| GB2537445A (en) * | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| WO2016082044A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| CA3045376C (en) * | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| EP3609580A4 (en) * | 2017-04-09 | 2021-03-24 | Combio Pharmaceutical, Inc. | COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE |
| US11530273B2 (en) * | 2017-05-23 | 2022-12-20 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing |
| MY204117A (en) * | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) * | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| EP3762030A4 (en) * | 2018-03-09 | 2022-01-05 | Phanes Therapeutics, Inc. | ANTI-CD73 ANTIBODIES AND USES THEREOF |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
-
2020
- 2020-11-13 CA CA3161717A patent/CA3161717A1/en active Pending
- 2020-11-13 WO PCT/US2020/060434 patent/WO2021097223A2/en not_active Ceased
- 2020-11-13 PH PH1/2022/551150A patent/PH12022551150A1/en unknown
- 2020-11-13 BR BR112022009317A patent/BR112022009317A2/pt unknown
- 2020-11-13 IL IL292959A patent/IL292959A/en unknown
- 2020-11-13 JP JP2022527957A patent/JP7789667B2/ja active Active
- 2020-11-13 MX MX2022005866A patent/MX2022005866A/es unknown
- 2020-11-13 EP EP20821493.2A patent/EP4058150A2/en active Pending
- 2020-11-13 CN CN202080092714.3A patent/CN115003385A/zh active Pending
- 2020-11-13 AU AU2020384305A patent/AU2020384305A1/en active Pending
- 2020-11-13 US US17/775,446 patent/US20220403041A1/en active Pending
- 2020-11-13 KR KR1020227019869A patent/KR20220100929A/ko active Pending
-
2022
- 2022-06-10 CO CONC2022/0008204A patent/CO2022008204A2/es unknown
-
2025
- 2025-10-03 JP JP2025167073A patent/JP2026026484A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026026484A (ja) | 2026-02-17 |
| US20220403041A1 (en) | 2022-12-22 |
| PH12022551150A1 (en) | 2023-10-09 |
| WO2021097223A2 (en) | 2021-05-20 |
| JP2023503846A (ja) | 2023-02-01 |
| KR20220100929A (ko) | 2022-07-18 |
| EP4058150A2 (en) | 2022-09-21 |
| IL292959A (en) | 2022-07-01 |
| CA3161717A1 (en) | 2021-05-20 |
| JP7789667B2 (ja) | 2025-12-22 |
| AU2020384305A1 (en) | 2022-06-30 |
| CO2022008204A2 (es) | 2022-06-21 |
| BR112022009317A2 (pt) | 2022-08-09 |
| CN115003385A (zh) | 2022-09-02 |
| WO2021097223A3 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551150A1 (en) | Biparatopic cd73 antibodies | |
| PH12022550509A1 (en) | Anti-cd73 antibodies | |
| MY208022A (en) | Anti-claudin 18.2 antibody and application thereof | |
| ZA201901924B (en) | Anti¿lag¿3 antibodies and compositions | |
| SA520420801B1 (ar) | أil جسام مضادة لـ -11 | |
| MX2022006992A (es) | Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente. | |
| MX2021000347A (es) | Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. | |
| PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| WO2020014473A8 (en) | TGFβ1 INHIBITORS AND USE THEREOF | |
| TN2012000555A1 (en) | Antibodies to human gdf8 | |
| MY193821A (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| MA53765B2 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| EP4009948A4 (en) | USE OF TGF-ALPHA POLYPEPTIDES OR ANTI-TGF-ALPHA ANTIBODIES FOR TREATING DISEASES AND DISORDERS | |
| PH12022550647A1 (en) | Anti-stem cell factor antibodies and methods of use thereof | |
| EP3896089A4 (en) | USE OF IL-15 PROTEIN COMPLEXES IN CONJUNCTION WITH PD-L1 ANTIBODIES FOR THE TREATMENT OF TUMOR DISEASES | |
| PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| SG11202112352TA (en) | Expression of antigen-binding proteins in the nervous system | |
| WO2020186111A3 (en) | Vista-binding antibodies and uses thereof | |
| WO2021058795A3 (en) | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof | |
| HK40081135A (en) | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |